CIK 0001677077
- Emerging growth company
Alzamend Neuro, Inc.
Sign in to watch- Ticker
- ALZN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Apr 30
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 811822909
- Phone
- +1 844-722-6333
- Business address
- 480 PEACHTREE ROAD NE, SECOND FLOOR, SUITE 103, ATLANTA, GA, 30326
- 4 Open-market buy 10% owner bought 16,400 shares at an average $3.62 ($59,379)
- 4 Open-market buy 10% owner bought 5,600 shares at an average $4.06 ($22,715)
- 4 Open-market buy 10% owner bought 1,500 shares at an average $4.24 ($6,360)
- 4 Open-market buy 10% owner bought 1,340,333 shares at an average $1.52 ($2,031,863)
- 4 Open-market buy 10% owner bought 12,500 shares at an average $5.08 ($63,554)
- 4 Open-market buy 10% owner bought 3,000 shares at $5.20 ($15,605)
- 4 Open-market buy 10% owner bought 5,300 shares at an average $5.63 ($29,818)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4/A Open-market buy 10% owner bought 14,500 shares at an average $6.15 ($89,136)
- 4 Open-market buy 10% owner bought 14,000 shares at an average $6.37 ($89,136)
- 4 Open-market buy 10% owner bought 14,000 shares at an average $6.65 ($93,109)
- 4 Open-market buy 10% owner bought 26,000 shares at an average $7.53 ($195,661)
- 4 Open-market buy 10% owner bought 24,300 shares at an average $9.15 ($222,339)
- 4 Open-market buy 10% owner bought 12,000 shares at an average $8.39 ($100,680)
- 4 Open-market buy 10% owner bought 74,000 shares at an average $9.29 ($687,117)
- 3 Insider Initial Statement of Ownership
- 4 Open-market buy 10% owner bought 2,000,000 shares at $5.00 ($10,000,000)
Page 8 of 9 · 170 filings